Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.55 |
| ▸ | ITGAV | P06756 | 8/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | MC4R | P32245 | 8/20 | 0.54 |
| ▸ | MC5R | P33032 | 8/20 | 0.54 |
| ▸ | MC3R | P41968 | 8/20 | 0.54 |
| ▸ | MC1R | Q01726 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18968795 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL7743878 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL16946584 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12547669 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL7743533 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL19605481 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13107808 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL14885799 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21475019 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL16938095 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040244-A1 | p-BORONOPHENYLALANINE DERIVATIVE AND COMPOSITION CONTAINING SAME, AND KIT FOR PRODUCING SAID DERIVATIVE AND COMPOSITION | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20150071872-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20100099644-A1 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE | REXAHN PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100099644-A1 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE | REXAHN PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | ITGB3 506/4885ITGAV 1552/4885ITGB5 1164/4885 |
| US-20210040244-A1 | p-BORONOPHENYLALANINE DERIVATIVE AND COMPOSITION CONTAINING SAME, AND KIT FOR PRODUCING SAID DERIVATIVE AND COMPOSITION | KIT, SETD7, PAH | ITGB3 4261/4885ITGAV 4066/4885ITGB5 3094/4885 |
| US-20100099644-A1 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE | HPGDS, HDGF, DPYD | ITGB3 1304/4885ITGAV 1983/4885ITGB5 1727/4885 |
| US-20150071872-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | ITGB3 506/4885ITGAV 1552/4885ITGB5 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.